Relay Therapeutics (RLAY) Receivables - Other (2020 - 2023)

Relay Therapeutics (RLAY) has 4 years of Receivables - Other data on file, last reported at $4.9 million in Q1 2023.

• Receivables - Other for Q1 2023 came in at $4.9 million, up 5.73% year-over-year; the trailing twelve-month figure through Mar 2023 was $4.9 million (up 5.73% YoY), and the FY2022 annual result was $4.9 million, up 8.29% from the prior year.
• Receivables - Other improved to $4.9 million in Q1 2023 per RLAY's latest filing, from $4.9 million in the prior quarter.
• Over five years, Receivables - Other peaked at $8.6 million in Q1 2021 and troughed at $4.2 million in Q2 2021.
• A 4-year average of $5.3 million and a median of $4.8 million in 2022 frame the typical range for Receivables - Other.
• On a YoY basis, Receivables - Other climbed as much as 14.7% in 2022 and fell as far as 45.65% in 2022.
• A 4-year view of Receivables - Other shows it stood at $7.7 million in 2020, then slumped by 40.72% to $4.5 million in 2021, then gained by 8.29% to $4.9 million in 2022, then gained by 0.65% to $4.9 million in 2023.
• Business Quant data shows RLAY's Receivables - Other at $4.9 million in Q1 2023, $4.9 million in Q4 2022, and $4.9 million in Q3 2022.